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NTCPPurpose: To test the hypothesis that delineation of swallowing organs at risk (SWOARs) based on
different guidelines results in differences in dose–volume parameters and subsequent normal tissue
complication probability (NTCP) values for dysphagia-related endpoints.
Materials and methods: Nine different SWOARs were delineated according to ﬁve different delineation
guidelines in 29 patients. Reference delineation was performed according to the guidelines and
NTCP-models of Christianen et al. Concordance Index (CI), dosimetric consequences, as well as differences
in the subsequent NTCPs were calculated.
Results: The median CI of the different delineation guidelines with the reference guidelines was 0.54 for
the pharyngeal constrictor muscles, 0.56 for the laryngeal structures and 0.07 for the cricopharyngeal
muscle and esophageal inlet muscle. The average difference in mean dose to the SWOARs between the
guidelines with the largest difference (maxDD) was 3.5 ± 3.2 Gy. A mean DNTCP of 2.3 ± 2.7% was found.
For two patients, DNTCP exceeded 10%.
Conclusions: The majority of the patients showed little differences in NTCPs between the different
delineation guidelines. However, large NTCP differences >10% were found in 7% of the patients. For cor-
rect use of NTCP models in individual patients, uniform delineation guidelines are of great importance.
 2014 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 111 (2014) 148–152
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/3.0/).In head and neck radiotherapy, reducing the dose to healthy
tissues is important, since radiation damage to organs at risk
(OARs) may result in severe complications during and after
completion of treatment. Some radiation-induced complications,
in particular swallowing dysfunction, have a signiﬁcant impact
on health-related quality of life as reported by patients [1,2].
Several guidelines for OAR delineation have been published
[3–11]. However, the deﬁnition, selection and delineation of OARs
vary widely among the different publications and authors. This
may lead to unjustiﬁed comparisons between institutes that apply
different guidelines, jeopardizing the translation of results
published into routine clinical practice.
Studies on the development of normal tissue complication
probability (NTCP) models have identiﬁed numerous predictive
factors for the development of radiation-induced dysphagia, suchas the radiation dose to anatomical structures involved in
swallowing dysfunction (e.g. the superior pharyngeal constrictor
muscle) [12]. NTCP models can be used to estimate the risk of a
given complication. Moreover, the most important dose volume
parameters included in these NTCP-models can be used for treat-
ment plan optimization, and thus to compare different radiation
treatment plans in order to select the most optimal treatment.
Radiation doses to speciﬁc swallowing organs at risk (SWOARs)
are main parameters for the calculation of NTCPs of dysphagia.
NTCPs directly result from speciﬁc dose parameters of the
SWOARs. However, if the delineation of SWOARs markedly differs
from the guidelines used for NTCP-model development, the
translation of the results of such models into routine clinical
practice may be incorrect.
Recently, Christianen et al. [12] published delineation guide-
lines for SWOARs in head and neck radiotherapy that differ at some
points from the deﬁnitions of SWOARs and subsequent delineation
guidelines used by other investigators [4–11]. So far, the magni-
tude of these differences is still unclear, and the possible clinical
relevance regarding differences in corresponding NTCPs remains
to be determined.
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the hypothesis that SWOAR delineations based on different delin-
eation guidelines lead to differences in dose–volume parameters
and subsequent NTCPs for dysphagia.Materials and methods
Delineation guidelines and patients
For the purpose of the present study, the guidelines as proposed
by Christianen et al. were used as a reference [3]. We decided to
use this publication as a reference as it was the only one dedicated
to the description of SWOARs delineation guidelines and because
these guidelines were actually used in a subsequent publication
that reported on the development of multivariate NTCP-models
for different endpoints related to dysphagia [12]. This publication
also included an overview of eight other guidelines for delineation
of SWOARs that were published between 2000 and 2010 [4–11].
The following SWOARs were included in this overview: the
pharyngeal constrictor muscles (PCMs), cricopharyngeal muscle
and ‘esophageal inlet muscle’ (EIM) (which was previously
described as ‘1 cm of the muscular compartment of the esophageal
inlet’ (10) and ‘upper esophageal sphincter’ (9)) and the glottic and
supraglottic larynx. For the purpose of the current study, we
extracted the deﬁnitions from the original papers and deﬁned
different delineation groups (DGs) by clustering the structures into
groups with corresponding deﬁnitions (Table S1). These groups
with corresponding deﬁnitions will be referred to as ‘DG1’, ‘DG2’,
etc..
The information in Table S1 was conﬁned to the deﬁnitions of
the cranial and caudal borders of the SWOARs, since the deﬁnitions
of these borders showed the largest variation. A detailed descrip-
tion of all remaining borders can be found elsewhere [3].
SWOARs were delineated in Pinnacle3 v9.0 (Philips, Madison) in
29 sample patients from our clinic according to the different
guidelines of the DGs, resulting in a total number of 899 contoured
SWOARs. Contouring was performed by one observer (EG) andFig. 1. Swallowing organs at risk (SWOARs) according to the different delineation gchecked by two others (MK and RS). The contours according to
all DGs of the SWOARs which are input to the studied NTCP-
models [12] are shown in Fig. 1.
Patients were randomly selected from our previous cohort [12].
The set comprised 6 laryngeal, 4 hypopharyngeal, 1 oral cavity, 15
oropharyngeal and 3 nasopharyngeal patients [13]. Planning
computed tomography (CT)-scans were acquired in supine
position with a 2 mm slice thickness.Geometric comparison
Geometric differences between the DGs were expressed as the
Concordance Index (CI) of different DGs with the reference DG
(DG1). The CI provides information on volume as well as on
positional differences.[14] The CI is the ratio of the intersection
(Volume1\Volume2) and union (Volume1[Volume2) volume of
two delineated volumes. A CI of 1.00 indicates perfect overlap
(identical structures),whereas a CI of 0.00 indicates no overlap at all.Dosimetric comparison
Standard clinically acceptable photon intensity modulated
radiation therapy (IMRT) treatment plans were available for all
patients. Plans were reviewed and/or replanned by a single
experienced dosimetrist (HPL) for the purpose of plan consistency.
When replanning (plan adjustment) was performed, this was done
to make sure that: (1) Coverage of the planning target volumes
(PTV) was adequate (exactly 98% of the PTV should receive 95%
of the prescribed dose); (2) The mean dose in the parotid glands
was as low as possible; (3) The dose outside the PTV was reduced
as much as possible (optimized dose conformity). No efforts were
taken to speciﬁcally reduce the dose to the SWOARs [13]. Thus,
the IMRT treatment plans were not inﬂuenced by the SWOARs
delineations.
We studied the differences in mean doses in the SWOARs
between the different DGs. For each patient the two DGs that
resulted in the largest difference in mean dose (maxDD) for aroups (DGs) in one patient. Sagittal view. PCM = pharyngeal constrictor muscle.
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patients to obtain an average maxDD per SWOAR. Estimates of
the variability in this study are always reported as ±1 standard
deviation (SD).
NTCP comparison
NTCPs were estimated for DG1 and DG2, in order to translate
the differences in dose to differences in NTCPs. This will demon-
strate the deviation from the model (DNTCP) in the situation of a
clinical practice in which the contouring guidelines of DG2 are
achieved, while the NTCP model belonging to DG1 is adopted.
The analysis was conﬁned to DG2 since it contained the most com-
plete set of SWOARs’ description in relation to DG1. Differences in
the NTCPs between DG1 and DG2 (DNTCP) were calculated for
each patient, based on four equations published by Christianen
et al. [12]. The NTCP-models contained the endpoints:
– swallowing dysfunction grade 2–4 at 6 months after completion
of radiotherapy, according to the RTOG Late Radiation
Morbidity Scoring Criteria (1)
– patient-rated moderate-to-severe problems with swallowing
solid (2), soft (3) and liquid (4) food
Table 1 lists the various parameters in the four different NTCP
models. Radiation technique was IMRT for all patients in this study.
Details on the NTCP calculation can be found in the Supplemental
Material.
Results
Geometric Comparison
A statistically signiﬁcant difference in SWOAR volume was
observed between the different DGs (p < 0.05, two-way ANOVA,
Table S2). Fig. S1 illustrates the CI of the different DGs reference
to DG1 for each SWOAR. The average median CI value was 0.54
for the PCMs, 0.56 for the laryngeal structures and 0.07 for the
cricopharyngeal muscle and EIM. For the cricopharyngeal muscle
no overlap at all with DG1 was seen (CI = 0). CIs of a certain DG
reference to DG1 varied between patients due to different anatomy
and/or different ﬂexion of the neck.Dosimetric comparison
Differences in SWOAR mean dose between the DGs showed
moderate to large variations (Fig. S2). Largest maxDD was found
for patient 11, for which the difference in mean dose to the PCM
superior between DG1 and DG3 was 19.1 Gy. The average maxDD
of all SWOARs was 3.5 ± 3.2 Gy with the largest differences
observed for the total PCM (6.0 ± 3.4 Gy), while differences for
the glottic larynx (0.8 ± 0.9 Gy) remained limited.NTCP comparison
Fig. 2 depicts DNTCP between DG1 and DG2 for the four
NTCP-models studied. The mean absolute DNTCP over all patientsTable 1
Parameters in the NTCP models for the four studied endpoints considering swallowing dy
NTCP model Parameters
superior PCM Middle PCM Supraglottic larynx EIM
RTOG grade 2–4 Mean dose (Gy) Mean dose (Gy)
Solid food Mean dose (Gy) Mean dose (Gy)
Soft food Mean dose (Gy)
Liquids Mean dose (Gy)and complications was 2.3 ± 2.7%. Differences were related to
patient’s anatomy, posture and primary tumour site. Patients with
tumours located in the oropharynx or nasopharynx showed higher
NTCPs for the DG1-based SWOARs, while for patients with tu-
mours located in the larynx and hypopharynx, the DG2-based
SWOARs showed the highest NTCPs (grey vs. white bars in Fig. 2,
respectively). This is mainly due to the larger overlap between
the planning target volume (PTV) and the DG1-based SWOARs
with respect to the DG2-based SWOARs for oropharynx/nasophar-
ynx patients, and vice versa for larynx/hypopharynx patients. For
two patients, the absolute DNTCP for at least one of the endpoints
was larger than 10%. For patient 12 (primary tumour location in
oropharynx), the mean dose to the supraglottic larynx according
to DG1 was 70.5 Gy and for DG2 57.7 Gy (Fig. 3). The resulting
DNTCP for RTOG grade 2–4 swallowing dysfunction was 11.6%
(61.6 vs. 50.0%). For problems with swallowing solid food, DNTCP
was 14.5% (47.3% vs. 32.8%). For the other patient (primary tumour
located in oropharynx), DNTCP was 10.9% (35.0% vs. 24.1%) for the
endpoint swallowing soft food (Fig. 2).Discussion
This is the ﬁrst study on the effect of variation in delineation
guidelines on dose and subsequent NTCPs. We showed that dose
parameters and corresponding NTCPs may vary widely depending
on the deﬁnitions of the SWOARs. For the set of head and neck
SWOARs included in the present study, the average maximal dose
difference (maxDD) was 3.5 ± 3.2 Gy. The translation of the dose
variation to variation in NTCP for DG1 vs. DG2 resulted in a mean
absolute DNTCP of 2.3 ± 2.7% (average over all patients and all four
NTCP models studied). On average this seems a moderate differ-
ence, but it should be stressed that in individual cases DNTCP
was much larger (>10%), which may lead to incorrect NTCP-predic-
tions and possibly unjustiﬁed clinical decisions.
The magnitude of deviations from the reference volumes, dose,
and subsequent NTCPs depended on patient’s anatomy and pos-
ture, as well as on primary tumour site. The impact of the variation
in patient anatomy was illustrated well in the box plots of the CI of
Fig. S1 (large interquartile distances). This spread of CI values may
be explained by the fact that for some patient anatomies and pos-
tures, the demarcations (e.g. certain bone and muscle structures) of
different DGs may be more separated than for other cases. For
example, patients with primary tumour sites located in the oro-
pharynx or nasopharynx showed relatively large differences in
NTCPs due to dose variation in the supraglottic larynx, while these
differences were much smaller for laryngeal and hypopharyngeal
cancers. According to DG1, the supraglottic larynx extends to the
tip of the epiglottis, while according to DG2 the cranial border ends
at the upper extension of the piriform sinus and aryepiglottic fold.
Therefore, the overlap of the supraglottic larynx with the PTV in
oropharyngeal cancer will generally be larger when using DG1
compared to DG2, resulting in higher dose values for DG1 com-
pared to DG2 (Fig. 3). Therefore, the NTCP for patient-rated moder-
ate-to-severe problems with solid, soft and liquid food (for which
the model includes the mean dose to the supraglottic larynx)sfunction [12].
Radiation technique Age (y) Tumour site
18–65/65+
3DCRT/IMRT 18–65/65+ Oropharynx, Nasopharynx/Hypopharynx,
Larynx, Oral Cavity
3DCRT/IMRT
Fig. 2. Difference in normal tissue complication probabilities (DNTCP) between delineation group (DG) 1 and 2 for different complications [12]. DNTCP > 0 means
underestimation and DNTCP < 0 means overestimation of the NTCP using DG2 in relation to DG1. Tumour location is indicated by grey/white ﬁlling of the bars.
Fig. 3. Dose distribution (sagittal view) and dose–volume histogram of the supraglottic larynx for a patient showing large differences between DG (delineation group) 1 and 2.
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moderate-to-severe problems with swallowing soft food, applying
DG2 for contouring the middle PCM also resulted in underestima-
tion of the NTCPs for patients with primary tumours located in the
oropharynx in relation to DG1 due to less overlap of the PTV with
the SWOAR using DG2.
The large differences in NTCPs in some individual patients
emphasize the importance of uniform delineation guidelines. We
propose to develop general consensus guidelines, which should
be simple and unambiguously described. Probably, current delin-
eation guidelines differ most because of different interpretation
of anatomy, and different choices for (derived) structure borders.
However, before we will be able to deﬁne a pragmatic set of simple
delineation guidelines, we believe it is important to study dose–
response relationships for swallowing problems more extensively
and to understand the physiology of side effects, to be able to
include the best predictive parameters in NTCP models. The
(superior) pharyngeal constrictor muscles [15,16] and the
supraglottic larynx [15] were, similar to our own research [12],
recently associated with late radiation induced dysphagia. Besides,De Ruyck et al. found that the rs3213245 (XRCC1) polymorphism
was associated with radiation induced dysphagia [16]. Integrating
biological and genetic (polymorphisms) information is promising
to improve and individualize NTCP models.
Consensus meetings, multi-modality imaging, and the use of
auto delineation tools could facilitate the introduction of uniform
delineation guidelines [17,18]. The ﬁndings of this study may also
have implications for the design of clinical trials, especially when
radiation-induced dysphagia is a primary or secondary endpoint.
In these cases (automated) review of delineations is recommended.
Although there still may be differences resulting from interob-
server variability, the concordance of head and neck OAR delinea-
tions within a guideline appears to be better than those between
guidelines (results of this study) [19].
Feng and colleagues [20] reported on the effect of contouring
variability and the resulting impact on IMRT treatment plan
optimization in oropharyngeal cancer. A contouring variability up
to 1.4 cm led to a 0.9 Gy mean difference between optimizations.
We can, however, not compare the results of that study with our
results, since these investigators studied variation in delineation
152 Differences in delineation guidelinesof repeated delineations by a group of experts, while the current
study focussed on inter-guideline variation. Moreover, these inves-
tigators studied dose differences between optimizations (thus be-
tween different treatment plans) on different contours, while we
studied the effect of using different guidelines for NTCP estimation
within one treatment plan.
From a scientiﬁc point of view, it is important to externally val-
idate NTCP-models developed in speciﬁc institutions, before they
can be used in routine clinical practice. The results of the present
study clearly illustrate that this external validation may be ham-
pered by inconsistencies in delineation guidelines. This is particu-
larly true for SWOARs with large dose variation and for NTCP-
models for which the results are more sensitive to differences in
contouring. Previous work has shown that the way we measure
dysphagia (physician-rated, patient-reported, or objective mea-
surements) is also of main importance for consistent NTCP model-
ling [21]. Therefore, clear deﬁnitions of organs at risk and endpoints
are required to improve the external validity of NTCP-models.
The present study showed the consequences of not applying the
matching input data to NTCP-models. In theory, all delineation
guidelines would ﬁt their own NTCP models. In practice however,
multiple model versions should be constructed and validated,
and this would also rule out pooling of dose–volume and follow-
up data into large data sets to build a proper NTCP-model. We
would therefore strongly advocate the use of uniform guidelines
for NTCP-modelling studies as well as for studies on external vali-
dation and routine clinical practice.
In the current study, mean dose and corresponding NTCP differ-
ences between DGs were compared using IMRT plans that were not
optimized based on the dose to the SWOARs, but particularly on the
dose to the parotid glands. Therefore, the question arises what hap-
pens with the dose differences if the IMRT plans would be opti-
mized for the different DGs. We expect the dose differences
between the DGs to be similar or even larger when optimization
on SWOARs would be performed, since dose gradients would be lo-
cated closer to the SWOARs, resulting in larger dose differences be-
tween the different DGs. SWOAR optimization for different DGswas
performed in two of our study patients, and results conﬁrmed our
presumption (see Supplemental Material II. for a case example).
Conclusion
The majority of the patients showed little differences in NTCPs
for different delineation guidelines. However, large NTCP differ-
ences >10% were found in 7% of the patients. For correct use of
NTCP models in individual patients uniform delineation guidelines
are of great importance.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.radonc.2014.01.
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